Navigation Links
Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
Date:9/6/2011

begin this year, will be a larger study also involving renal patients. Hospira is consulting with the U.S. Food and Drug Administration (FDA) to plan the trial, which will take place at U.S. hemodialysis centers.

Hospira already sells a biosimilar EPO in Europe, Retacrit™, and is the first and only North American-headquartered company with biosimilars on the European market. Retacrit, introduced in early 2008, now has a more than 50 percent share of the total short-acting EPO biosimilar market in Europe. In addition, Hospira launched Nivestim™, a biosimilar version of filgrastim, in Europe in 2010 and in Australia earlier this year. Filgrastim is a granulocyte colony-stimulating factor (G-CSF) used to treat neutropenia, a condition in which the body makes too few infection-fighting white blood cells. The condition is often caused by drugs prescribed for cancer treatment.

Hospira's Phase I study was conducted with the participation of DaVita Inc. (NYSE: DVA) and Fresenius Medical Care AG & Co. KGaA (NYSE: FMS, FMS/P). Although Phase I trials are most often conducted with healthy volunteers, Hospira received FDA approval to conduct its Phase I trial with renal patients.

Biosimilars are high-quality, cost-effective alternatives to proprietary biopharmaceuticals, which are large-protein molecules derived from genetically modified cell lines. In contrast, "traditional" pharmaceuticals are made from small-molecule, chemical substances. With a growing number of patents for biopharmaceuticals expiring in the United States and around the globe, Hospira has significantly expanded its comprehensive competencies to develop, manufacture and market biosimilars, and has one of the largest biosimilar pipelines in the industry. Hospira's entrance into the biosimilar pharmaceutical market is a natural extension of its leading global generic injectable pharmaceuticals
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hospira to Host 2011 Investor Day
2. Hospira to Present at the Morgan Stanley Global Healthcare Conference
3. Hospira Expands Board of Directors
4. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
5. Hospira Reports Second-Quarter 2011 Results
6. Hospira to Host Conference Call for Second-Quarter 2011 Results
7. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
8. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
9. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
10. Hospira Reports First-Quarter 2011 Results
11. Hospira Board Authorizes $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Indiana blocked the sale of ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... FAIRFIELD, N.J., Jan. 28, 2011 The Healthcare ... of the Year" is Freda Lewis-Hall, MD, chief medical ... Dr. Lewis-Hall has held leadership roles in direct ... (Photo: http://photos.prnewswire.com/prnh/20110128/DC38263 ) ...
... 2011 TechniScan (OTC Bulletin Board: TSNI ... and commercialization of an automated 3D breast ultrasound imaging ... will present at RetailInvestorConferences.com. DATE: , February 3rd, ... This will be a live, interactive online event where ...
Cached Medicine Technology:Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 2Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 3Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 4TechniScan to Present Live, Online at RetailInvestorConferences.com on February 3rd 2
(Date:8/21/2014)... August 21, 2014 AVEC Health ... announce the addition of Kerry Gillespie as Chief ... healthcare management experience, Gillespie brings an extremely robust ... executive management positions with prominent industry leading organizations ... as President of Triad Isotopes, Inc. a private ...
(Date:8/21/2014)... (PRWEB) August 22, 2014 Top10BestSEOHosting.com ... and announces that iPage ( http://www.top10bestseohosting.com/go/iPage/ ) is ... in 2014. , The manager of Top10BestSEOHosting.com ... cheap hosting supplier. Actually, these companies have outperformed ... and customer support. People can get the best ...
(Date:8/21/2014)... Living in a quality residential community ... along with it. A quality Home Owners Association like ... are available. , Simpson Mill Plantation, ... Community Association Management, LLC made a recent investment in ... provide an additional amenity for their neighborhood. , Situated ...
(Date:8/21/2014)... in the coronary arteries of chronic kidney disease patients ... according to a new study in the Journal ... ). Researchers at the Johns Hopkins Bloomberg School of ... commonly used measures of subclinical atherosclerosis in predicting the ... , Approximately 50 percent of all patients with chronic ...
(Date:8/21/2014)... Improv performers from Fun House Theatre ... at Silverado Turtle Creek memory care community in Dallas. ... ranging from ages 10 to 16, delivers a groundbreaking ... set. The troupe's philosophy is that improv is based ... to touch audiences regardless of their circumstance — including ...
Breaking Medicine News(10 mins):Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2Health News:iPage Reviews Unveiled Online At Top10BestSEOHosting.com 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 3Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2
... triggered by abortion. However critics term it as an ... that 72% of women who terminated their pregnancies were ... the first four years after their pregnancy than women ... indicated that Women who had an abortion were nearly ...
... Research conducted at Melbourne on skin cancer could save thousands ... than 15 per cent of melanoma cancers but caused up ... melanomas. The research shows the pimple-like melanoma is the most ... severe sunburn can cause a nodular melanoma. It appears anywhere ...
... their country has its first known case of SARS. A ... signs of SARS virus. Health officials sent sent lab samples ... the health ministry said analysis had not yet confirmed the ... the Amur region, which has a booming cross-border trade, closed ...
... deadly brain-wasting diseases might be just what the researchers ... Abnormal proteins called the prions resultantly cause a brain-wasting ... encephalopathy, or mad cow disease in humans. The presence ... together. CJD is usually found in large numbers// in ...
... the past this mask has been well tested whenever ... infection. During all the previous instances around the world for example ... danger this mask was used. SARS or severe acute ... mask to use to protect against infection.. ,Hoarding of ...
... two overlapping genes responsible for bipolar disorder. In previous ... This leads to the idea that the genes may ... as manic-depressive illness, is a brain disorder that causes ... energy and elation alternating with longer periods of fatigue ...
Cached Medicine News:Health News:Brain diseases an outcome of cannibalism, 2
5L...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... Family includes fixed-volume, adjustable-volume, and multichannel ... Eppendorf Research pro Pipette. Designed with ... high-performance pipettes have earned a worldwide ... use with original Eppendorf pipette tips, ...
10L...
Medicine Products: